CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
The pharmaceutical industry stands at a pivotal juncture – one defined by digital transformation reshaping operations, the ethical and business imperative that is sustainability, and truly collaborative partnerships that are unlocking innovation at an unprecedented scale. The CPHI Pharma Awards 2026 aim to celebrate the breakthroughs and purposeful work defining the industry's future.
The evolution of the pharmaceutical industry has similarly shaped our 2026 programme and the future of CPHI events. We have refined and expanded our award categories to capture these emerging trends: integrated delivery solutions, ecosystem-enabling innovation, environmental leadership, and partnership excellence that creates systemic change.
Dynamic categories for a changing industry
Leading this evolution of the CPHI Pharma Award categories, Digital Transformation celebrates organisations achieving measurable operational gains through strategic technology adoption, modernising workflows, and delivering competitive advantage. Building on this foundation, the Innovation Catalyst award represents our most forward-thinking addition; in recognising foundational innovations that enable others to build and connect, we hope to celebrate the power of collaboration in driving innovation. These platforms, standards, and frameworks create multiplier effects across the pharmaceutical ecosystem, amplifying the digital revolution's impact on the wider pharmaceutical industry.
Sustainability and partnerships redefined
Recognising sustainability's growing complexity, we have rethought and reshaped this area, splitting it into two refined categories. The Sustainable Pharma Excellence award spotlights transformative environmental innovations, from breakthrough green chemistry to clean manufacturing technologies and circular economy initiatives. Complementing individual excellence, the Sustainable Transformation Partnership award celebrates cross-sector partnerships delivering systemic change through sustainable supplier networks and strategic alliances that create lasting impact beyond individual organisations.
This collaborative spirit extends throughout our partnership categories. Our True Partnership Excellence award focuses on CDMOs/CMOs that transcend traditional service provision to become genuine innovation partners through collaboration and strategic value creation. Meanwhile, Excellence with Purpose celebrates initiatives proving that putting patients and communities first drives both meaningful social impact and sustainable business success – the ultimate partnership between industry and society.
The premier platform for pharmaceutical excellence
The CPHI Pharma Awards stand as the industry's most prestigious recognition programme, offering unparalleled reach across the global pharmaceutical ecosystem. This isn't just recognition; it is connection to the right partnerships, opportunities, and conversations that drive the industry forward.
Whether you have pioneered digital solutions, enabled ecosystem-wide innovation, delivered environmental breakthroughs, forged transformative partnerships, or championed patient-first initiatives, the CPHI Pharma Awards provide the perfect stage to showcase your impact. Your story could inspire the next wave of pharmaceutical innovation and connect you with partners who share your vision for the industry's future.
Don't miss this opportunity to gain global recognition and join the conversation shaping pharma's tomorrow. Submit your entry today — deadline is May 16, 2026. At the heart of Pharma.
Categories include: API Development and Innovation, CEO of the Year, Finished Formulation, Future Leader, Manufacturing Excellence, Start-Up Initiative, Supply Chain Excellence, Woman of the Year, Drug delivery devices and packaging innovation, Digital Transformation, Excellence with Purpose, Innovation Catalyst, Sustainable Pharma Excellence, Sustainable Transformation Partnership Award, and True Partnership Excellence.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile... -
News Eli Lilly eyes India as next global export hub
Eli Lilly and Co. is positioning India as a key player in its global supply chain, driven by the booming success of its diabetes and obesity drug, Mounjaro.